LEUKOCARE and Boehringer Ingelheim Enter into a LongTerm Agreement

Biotechnology company LEUKOCARE AG and Boehringer Ingelheim have entered into a license agreement in the field of veterinary diagnostics.
Under this agreement, Boehringer Ingleheim will be able to utlise biological reagents in a new verterinary diagnostics product through having access to LEUKOCARE’s formulation technologies. This will enable veterinarians to make decisions directly onsite, as samples can be analysed through portable devices, mimising delays and the cost of shipping samples.
Licence and payment terms are yet to be disclosed.

“Thanks to LEUKOCARE’s expertise and its SPS(R) technologies, we have been able to develop a new diagnostic concept in animal health,” comments Rolf-Dieter Günther, Head of Diagnostics at Boehringer Ingelheim, “The diagnostics platform will enable veterinarians to get a quick, easy and safe test to be performed directly at the stable or at the pet owner’s home.”

Michael Scholl, CEO of LEUKOCARE, said,
“After having already worked with Boehringer Ingelheim for a longer period of time and being closely involved in their development activities, we are delighted to support our partner with our SPS(R) technologies in this exciting application. This once again proves the high quality of our SPS(R) formulation technology platform, and, on the other hand, our outstanding development skills.”